Inventor
SCHAFER PETER H
US39 patents
⚠️ This page may combine multiple inventors who share the name “SCHAFER PETER H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
26 patentsUS6962940B2Nov 8, 2005
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CELGENE CORP107 citations99
US7893101B2Feb 22, 2011
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP44 citations98
US7427638B2Sep 23, 2008
(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
CELGENE CORP53 citations97
US7659303B2Feb 9, 2010
Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione
CELGENE CORP21 citations96
US7659302B2Feb 9, 2010
Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
CELGENE CORP35 citations96
US7507759B2Mar 24, 2009
Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione
CELGENE CORP21 citations96
US7358272B2Apr 15, 2008
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
CELGENE CORP21 citations96
US9724330B2Aug 8, 2017
Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CELGENE CORP7 citations93
US9283207B2Mar 15, 2016
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CELGENE CORP7 citations93
US9018243B2Apr 28, 2015
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP13 citations93
US8802717B2Aug 12, 2014
Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
CELGENE CORP13 citations93
US10047151B2Aug 14, 2018
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CELGENE CORP19 citations92
US7276529B2Oct 2, 2007
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CELGENE CORP28 citations90
US7208516B2Apr 24, 2007
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CELGENE CORP40 citations90
US10092542B2Oct 9, 2018
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CELGENE CORP4 citations84
US9857359B2Jan 2, 2018
Methods for determining drug efficacy using cereblon-associated proteins
CELGENE CORP11 citations81
US10751414B2Aug 25, 2020
Methods of treating psoriasis using PD-1 binding antibodies
CELGENE CORP9 citations78
US11660302B2May 30, 2023
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CELGENE CORP1 citations73
US10980812B2Apr 20, 2021
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CELGENE CORP2 citations73
US10596179B2Mar 24, 2020
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CELGENE CORP1 citations73
US10245266B2Apr 2, 2019
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CELGENE CORP3 citations73
US9433606B2Sep 6, 2016
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP3 citations73
US10919883B2Feb 16, 2021
Treatment of immune-related and inflammatory diseases
CELGENE CORP0 citations62
US12064437B2Aug 20, 2024
Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies
CELGENE CORP0 citations59
US11524950B2Dec 13, 2022
Treatment of immune-related and inflammatory diseases
CELGENE CORP0 citations58
US9480676B2Nov 1, 2016
Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis
CELGENE CORP0 citations42
MULLER GEORGE W
4 patentsUS8455536B2Jun 4, 2013
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
MULLER GEORGE W28 citations96
US8629173B2Jan 14, 2014
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
MULLER GEORGE W11 citations92
US8093283B2Jan 10, 2012
Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof
MULLER GEORGE W17 citations92
US8906932B2Dec 9, 2014
Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dione
MULLER GEORGE W15 citations81
AMGEN INC
3 patentsUS11260046B2Mar 1, 2022
(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AMGEN INC0 citations73
US11040024B2Jun 22, 2021
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AMGEN INC0 citations73
US10610516B2Apr 7, 2020
Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione
AMGEN INC1 citations73
SCHAFER PETER H
3 patentsUS8716252B2May 6, 2014
(Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses
SCHAFER PETER H2 citations54
US9387195B2Jul 12, 2016
Methods for treating diseases using isoindoline compounds
SCHAFER PETER H0 citations49
US9272035B2Mar 1, 2016
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
SCHAFER PETER H1 citations43